전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved381 programs
AntibodyLimited DatastaleRochePhase 2

Tocilizumab at emerging CRS (Tocilizumab at emerging CRS)

Myeloma; Lymphoma · Myeloma

#Myeloma#Antibody#Phase2#monoclonal-antibody#Lymphoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

Tocilizumab before CAR-T cell infusion (Tocilizumab before CAR-T cell infusion)

Myeloma; Lymphoma · Myeloma

#Myeloma#Antibody#Phase2#monoclonal-antibody#Lymphoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleHoffmann-La RochePhase 3

Tociluzumab (Tociluzumab)

Relapsed or Refractory Follicular Lymphoma · FRα

#FR#Antibody#Phase3#monoclonal-antibody#RelapsedorRefractoryFollicularLy+1
Trials 1Status Recruiting
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab combine with Rituximab (Toripalimab combine with Rituximab)

Diffuse Large B-cell Lymphoma; Rituximab · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#Antibody#Phase2#monoclonal-antibody#Rituximab+1
Trials 1Status Active
AntibodyLimited DatastaleJunshi BiosciencesPhase 2

Toripalimab, Rituximab (Toripalimab, Rituximab)

Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase2#monoclonal-antibody#High-gradeB-cellLymphoma+1
Trials 1Status Active
AntibodyLimited DatastaleGlaxoSmithKlinePhase 3

Tositumomab and Iodine I 131 Tositumomab (Tositumomab and Iodine I 131 Tositumomab)

Lymphoma, Non-Hodgkin · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase3#monoclonal-antibody#Lymphoma+2
Trials 1Status Active
CGTLimited DatastaleTimmune Biotech Inc.Phase 2

TriCAR-T-CD19 (TriCAR-T-CD19)

Non-hodgkin Lymphoma,B Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleShanghai Unicar-Therapy Bio-med…Phase 1

Triple-targeted CAR-T Therapy (Triple-targeted CAR-T Therapy)

B-cell Lymphoma · B-cell Lymphoma

#B-cellLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
CGTLimited DatastaleChinese PLA General HospitalPhase 2

UCART019 (UCART019)

B Cell Leukemia; B Cell Lymphoma · B Cell Leukemia

#BCellLeukemia#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleCellectis S.A.Phase 2

UCART20x22 (UCART20x22)

B-cell Non-Hodgkin Lymphoma (B-NHL) · B-cell Non-Hodgkin Lymphoma (B-NHL)

#B-cellNon-HodgkinLymphomaB-NHL#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleDavid WaldPhase 1

UF-KURE19 CAR-T cells (UF-KURE19 CAR-T cells)

Non Hodgkin Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Recruiting
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 1

Universal CD7-specific CAR gene-engineered T cells (Universal CD7-specific CAR gene-engineered T cells)

T-cell Acute Lymphoblastic Leukemia; T-cell Acute Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells (Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells)

B Cell Leukemia; B Cell Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleWellington Zhaotai Therapies Li…Phase 1

1928T2z CAR-T cells (WZTL002-1, WZTL002-1 (1928T2z CAR-T cells))

Lymphomas Non-Hodgkin's B-Cell; Diffuse Large B-cell Lymphoma (DLBCL) · Lymphomas Non-Hodgkin's B-Cell

#LymphomasNon-HodgkinsB-Cell#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleCABYCPhase 2

Y-90 Ibritumomab tiuxetan (Y-90 Ibritumomab tiuxetan)

Mantle Cell Lymphoma · Mantle Cell Lymphoma

#MantleCellLymphoma#Antibody#Phase2#monoclonal-antibody#CABYC
Trials 1Status Active
AntibodyLimited DatastaleThe First Affiliated Hospital w…Phase 2

Zebetuzumab (Zebetuzumab)

Marginal Zone Lymphoma(MZL) · Marginal Zone Lymphoma(MZL)

#MarginalZoneLymphomaMZL#Antibody#Phase2#monoclonal-antibody#The
Trials 1Status Recruiting
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 2

^111 In Ibritumomab Tiuxetan (^111 In Ibritumomab Tiuxetan)

Lymphoma · Lymphoma

#Lymphoma#Antibody#Phase2#monoclonal-antibody#MD
Trials 1Status Discontinued
CGTLimited DatastaleShanghai First Song Biotechnolo…Phase 1

anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells (anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells)

Relapsed/refractory Lymphoma; Relapsed/Refractory Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleShanghai General Hospital, Shan…Phase 1

anti-CD7 CAR-T cells (anti-CD7 CAR-T cells)

T Lymphoblastic Leukemia/Lymphoma; T-cell Acute Lymphoblastic Leukemia · T Lymphoblastic Leukemia/Lymphoma

#TLymphoblasticLeukemiaLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 2

apolizumab (apolizumab)

Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Small Lymphocytic Lymphoma · FRα

#FR#Antibody#Phase2#monoclonal-antibody#NoncontiguousStageIISmallLymphoc+2
Trials 1Status Active

18 / 20 pages

← PreviousNext →